Article Text

PDF
Case report
The first North American use of the Pipeline Flex flow diverter
  1. Edward AM Duckworth1,2,3,
  2. Christopher Nickele2,3,
  3. Daniel Hoit2,3,
  4. Andrey Belayev2,3,
  5. Christopher J Moran4,
  6. Adam S Arthur2,3
  1. 1Department of Neurosurgery, Baylor College of Medicine, Houston, Texas, USA
  2. 2Semmes-Murphey Neurologic and Spine Institute, Memphis, Tennessee, USA
  3. 3Department of Neurosurgery, University of Tennessee Health Sciences Center, Memphis, Tennessee, USA
  4. 4Department of Neuroradiology, Mallinkrodt Institute, St Louis, Missouri, USA
  1. Correspondence to Dr Adam S Arthur, Semmes-Murphey Neurologic and Spine Institute, Memphis, Tennessee 38120, USA; aarthur{at}semmes-murphey.com

Abstract

Flow diversion for the management of intracranial aneurysms represents a paradigm shift in how aneurysms are managed. The Pipeline embolization device (PED) is, to date, the only flow diverter approved for use in the USA by the Food and Drug Administration. Limitations and complications with new treatment strategies are inevitable, and with the PED there have been reports of complications, most commonly with challenging deployments. Once deployment has been initiated, the device is ‘one-way’; it can only be deployed further or removed. Yet, situations arise in which the ability to recapture or reposition the device would be advantageous. A second-generation Pipeline has been developed that addresses these concerns. We report the first use in North America of this second-generation Pipeline device: the Pipeline Flex. We discuss our rationale for using the device, our impressions of its operation, and the relevant literature concerning the current state of flow diversion.

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.